Androgen receptor - Revision history

Michael: /* See also */

2019-03-18T13:09:45Z

Michael: /* See also */

2019-03-18T13:09:12Z

Michael: antibodies

2019-03-18T13:08:06Z

antibodies

← Older revision		Revision as of 13:08, 18 March 2019
Line 22:		Line 22:
	*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal \| last1 = Honma \| first1 = N. \| last2 = Takubo \| first2 = K. \| last3 = Akiyama \| first3 = F. \| last4 = Sawabe \| first4 = M. \| last5 = Arai \| first5 = T. \| last6 = Younes \| first6 = M. \| last7 = Kasumi \| first7 = F. \| last8 = Sakamoto \| first8 = G. \| title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. \| journal = Histopathology \| volume = 47 \| issue = 2 \| pages = 195-201 \| month = Aug \| year = 2005 \| doi = 10.1111/j.1365-2559.2005.02181.x \| PMID = 16045781 }}</ref>		*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal \| last1 = Honma \| first1 = N. \| last2 = Takubo \| first2 = K. \| last3 = Akiyama \| first3 = F. \| last4 = Sawabe \| first4 = M. \| last5 = Arai \| first5 = T. \| last6 = Younes \| first6 = M. \| last7 = Kasumi \| first7 = F. \| last8 = Sakamoto \| first8 = G. \| title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. \| journal = Histopathology \| volume = 47 \| issue = 2 \| pages = 195-201 \| month = Aug \| year = 2005 \| doi = 10.1111/j.1365-2559.2005.02181.x \| PMID = 16045781 }}</ref>
	*[[Prostate carcinoma with amphicrine features]].<ref name=pmid28756619>{{Cite journal \| last1 = Prendeville \| first1 = S. \| last2 = Al-Bozom \| first2 = I. \| last3 = Compérat \| first3 = E. \| last4 = Sweet \| first4 = J. \| last5 = Evans \| first5 = AJ. \| last6 = Ben-Gashir \| first6 = M. \| last7 = Mete \| first7 = O. \| last8 = van der Kwast \| first8 = TH. \| last9 = Downes \| first9 = MR. \| title = Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin? \| journal = Histopathology \| volume = 71 \| issue = 6 \| pages = 926-933 \| month = Dec \| year = 2017 \| doi = 10.1111/his.13330 \| PMID = 28756619 }}</ref>		*[[Prostate carcinoma with amphicrine features]].<ref name=pmid28756619>{{Cite journal \| last1 = Prendeville \| first1 = S. \| last2 = Al-Bozom \| first2 = I. \| last3 = Compérat \| first3 = E. \| last4 = Sweet \| first4 = J. \| last5 = Evans \| first5 = AJ. \| last6 = Ben-Gashir \| first6 = M. \| last7 = Mete \| first7 = O. \| last8 = van der Kwast \| first8 = TH. \| last9 = Downes \| first9 = MR. \| title = Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin? \| journal = Histopathology \| volume = 71 \| issue = 6 \| pages = 926-933 \| month = Dec \| year = 2017 \| doi = 10.1111/his.13330 \| PMID = 28756619 }}</ref>

			==Antibodies==
			Various clone exist and they target different regions/variants; an incomplete list includes:
			*AR N-terminus.
			*AR C-terminus.
			*AR v7.

	==See also==		==See also==

Michael: tweak

2018-04-14T12:27:50Z

tweak

← Older revision		Revision as of 12:27, 14 April 2018
Line 15:		Line 15:
	\| Other =		\| Other =
	}}		}}
	'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone).		'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens ([[testosterone]], dihydrotestosterone).

	==Tumours with AR==		==Tumours with AR==

Michael at 16:11, 19 March 2018

2018-03-19T16:11:04Z

← Older revision		Revision as of 16:11, 19 March 2018
Line 21:		Line 21:
	*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal \| last1 = Kuhn \| first1 = E. \| last2 = Ayhan \| first2 = A. \| last3 = Shih \| first3 = IeM. \| last4 = Seidman \| first4 = JD. \| last5 = Kurman \| first5 = RJ. \| title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. \| journal = Eur J Cancer \| volume = 49 \| issue = 18 \| pages = 3839-49 \| month = Dec \| year = 2013 \| doi = 10.1016/j.ejca.2013.08.011 \| PMID = 24012099 }}</ref>		*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal \| last1 = Kuhn \| first1 = E. \| last2 = Ayhan \| first2 = A. \| last3 = Shih \| first3 = IeM. \| last4 = Seidman \| first4 = JD. \| last5 = Kurman \| first5 = RJ. \| title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. \| journal = Eur J Cancer \| volume = 49 \| issue = 18 \| pages = 3839-49 \| month = Dec \| year = 2013 \| doi = 10.1016/j.ejca.2013.08.011 \| PMID = 24012099 }}</ref>
	*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal \| last1 = Honma \| first1 = N. \| last2 = Takubo \| first2 = K. \| last3 = Akiyama \| first3 = F. \| last4 = Sawabe \| first4 = M. \| last5 = Arai \| first5 = T. \| last6 = Younes \| first6 = M. \| last7 = Kasumi \| first7 = F. \| last8 = Sakamoto \| first8 = G. \| title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. \| journal = Histopathology \| volume = 47 \| issue = 2 \| pages = 195-201 \| month = Aug \| year = 2005 \| doi = 10.1111/j.1365-2559.2005.02181.x \| PMID = 16045781 }}</ref>		*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal \| last1 = Honma \| first1 = N. \| last2 = Takubo \| first2 = K. \| last3 = Akiyama \| first3 = F. \| last4 = Sawabe \| first4 = M. \| last5 = Arai \| first5 = T. \| last6 = Younes \| first6 = M. \| last7 = Kasumi \| first7 = F. \| last8 = Sakamoto \| first8 = G. \| title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. \| journal = Histopathology \| volume = 47 \| issue = 2 \| pages = 195-201 \| month = Aug \| year = 2005 \| doi = 10.1111/j.1365-2559.2005.02181.x \| PMID = 16045781 }}</ref>
			*[[Prostate carcinoma with amphicrine features]].<ref name=pmid28756619>{{Cite journal \| last1 = Prendeville \| first1 = S. \| last2 = Al-Bozom \| first2 = I. \| last3 = Compérat \| first3 = E. \| last4 = Sweet \| first4 = J. \| last5 = Evans \| first5 = AJ. \| last6 = Ben-Gashir \| first6 = M. \| last7 = Mete \| first7 = O. \| last8 = van der Kwast \| first8 = TH. \| last9 = Downes \| first9 = MR. \| title = Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin? \| journal = Histopathology \| volume = 71 \| issue = 6 \| pages = 926-933 \| month = Dec \| year = 2017 \| doi = 10.1111/his.13330 \| PMID = 28756619 }}</ref>

	==See also==		==See also==

Michael at 01:36, 10 February 2016

2016-02-10T01:36:06Z

← Older revision		Revision as of 01:36, 10 February 2016
Line 1:		Line 1:
			{{ Infobox immunostain
			\| Name = {{PAGENAME}}
			\| Image =
			\| Width =
			\| Caption =
			\| Abbrev =
			\| Synonyms =
			\| Similar =
			\| Clones =
			\| Use =
			\| Subspecial =
			\| Pattern = nuclear
			\| Positive = [[salivary duct carcinoma]], [[Brenner tumour]], [[apocrine carcinoma of the breast]], [[prostate carcinoma]] (most cases)
			\| Negative =
			\| Other =
			}}
	'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone).		'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone).

Michael: /* Tumours with AR */

2016-02-10T01:17:58Z

Tumours with AR

← Older revision		Revision as of 01:17, 10 February 2016
Line 4:		Line 4:
	*[[Salivary duct carcinoma]] +ve ~90% of cases.<ref name=pmid10757407>{{Cite journal \| last1 = Fan \| first1 = CY. \| last2 = Wang \| first2 = J. \| last3 = Barnes \| first3 = EL. \| title = Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. \| journal = Am J Surg Pathol \| volume = 24 \| issue = 4 \| pages = 579-86 \| month = Apr \| year = 2000 \| doi = \| PMID = 10757407 }}</ref>		*[[Salivary duct carcinoma]] +ve ~90% of cases.<ref name=pmid10757407>{{Cite journal \| last1 = Fan \| first1 = CY. \| last2 = Wang \| first2 = J. \| last3 = Barnes \| first3 = EL. \| title = Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. \| journal = Am J Surg Pathol \| volume = 24 \| issue = 4 \| pages = 579-86 \| month = Apr \| year = 2000 \| doi = \| PMID = 10757407 }}</ref>
	*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal \| last1 = Kuhn \| first1 = E. \| last2 = Ayhan \| first2 = A. \| last3 = Shih \| first3 = IeM. \| last4 = Seidman \| first4 = JD. \| last5 = Kurman \| first5 = RJ. \| title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. \| journal = Eur J Cancer \| volume = 49 \| issue = 18 \| pages = 3839-49 \| month = Dec \| year = 2013 \| doi = 10.1016/j.ejca.2013.08.011 \| PMID = 24012099 }}</ref>		*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal \| last1 = Kuhn \| first1 = E. \| last2 = Ayhan \| first2 = A. \| last3 = Shih \| first3 = IeM. \| last4 = Seidman \| first4 = JD. \| last5 = Kurman \| first5 = RJ. \| title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. \| journal = Eur J Cancer \| volume = 49 \| issue = 18 \| pages = 3839-49 \| month = Dec \| year = 2013 \| doi = 10.1016/j.ejca.2013.08.011 \| PMID = 24012099 }}</ref>
			*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal \| last1 = Honma \| first1 = N. \| last2 = Takubo \| first2 = K. \| last3 = Akiyama \| first3 = F. \| last4 = Sawabe \| first4 = M. \| last5 = Arai \| first5 = T. \| last6 = Younes \| first6 = M. \| last7 = Kasumi \| first7 = F. \| last8 = Sakamoto \| first8 = G. \| title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. \| journal = Histopathology \| volume = 47 \| issue = 2 \| pages = 195-201 \| month = Aug \| year = 2005 \| doi = 10.1111/j.1365-2559.2005.02181.x \| PMID = 16045781 }}</ref>

	==See also==		==See also==

Michael: /* Tumours with AR */

2016-02-10T01:07:59Z

Tumours with AR

← Older revision		Revision as of 01:07, 10 February 2016
Line 3:		Line 3:
	==Tumours with AR==		==Tumours with AR==
	*[[Salivary duct carcinoma]] +ve ~90% of cases.<ref name=pmid10757407>{{Cite journal \| last1 = Fan \| first1 = CY. \| last2 = Wang \| first2 = J. \| last3 = Barnes \| first3 = EL. \| title = Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. \| journal = Am J Surg Pathol \| volume = 24 \| issue = 4 \| pages = 579-86 \| month = Apr \| year = 2000 \| doi = \| PMID = 10757407 }}</ref>		*[[Salivary duct carcinoma]] +ve ~90% of cases.<ref name=pmid10757407>{{Cite journal \| last1 = Fan \| first1 = CY. \| last2 = Wang \| first2 = J. \| last3 = Barnes \| first3 = EL. \| title = Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. \| journal = Am J Surg Pathol \| volume = 24 \| issue = 4 \| pages = 579-86 \| month = Apr \| year = 2000 \| doi = \| PMID = 10757407 }}</ref>
			*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal \| last1 = Kuhn \| first1 = E. \| last2 = Ayhan \| first2 = A. \| last3 = Shih \| first3 = IeM. \| last4 = Seidman \| first4 = JD. \| last5 = Kurman \| first5 = RJ. \| title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. \| journal = Eur J Cancer \| volume = 49 \| issue = 18 \| pages = 3839-49 \| month = Dec \| year = 2013 \| doi = 10.1016/j.ejca.2013.08.011 \| PMID = 24012099 }}</ref>

	==See also==		==See also==

Michael: create

2016-02-10T00:59:08Z

create

New page

'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone).

==Tumours with AR==
*[[Salivary duct carcinoma]] +ve ~90% of cases.<ref name=pmid10757407>{{Cite journal | last1 = Fan | first1 = CY. | last2 = Wang | first2 = J. | last3 = Barnes | first3 = EL. | title = Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. | journal = Am J Surg Pathol | volume = 24 | issue = 4 | pages = 579-86 | month = Apr | year = 2000 | doi = | PMID = 10757407 }}</ref>

==See also==
*[[Immunohistochemistry]].

==References==
{{Reflist|1}}

[[Category:Immunohistochemistry]]

← Older revision		Revision as of 13:09, 18 March 2019
Line 32:		Line 32:
	*[[Immunohistochemistry]].		*[[Immunohistochemistry]].
	*[[Enzalutamide]].		*[[Enzalutamide]].
			*[[Abiraterone]].

	==References==		==References==

← Older revision		Revision as of 13:09, 18 March 2019
Line 31:		Line 31:
	==See also==		==See also==
	*[[Immunohistochemistry]].		*[[Immunohistochemistry]].
			*[[Enzalutamide]].

	==References==		==References==